Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

NCT02468557 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT02468557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02468557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
July 30, 2015
Completion date
April 27, 2016
Enrollment
16 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

previously untreated pancreatic ductal adenocarcinoma, relapsed/refractory pancreatic ductal adenocarcinoma